-
Beijing GoBroad Hospital Clinical Trials Summary (November)
As the first international research-oriented hospital in China, Beijing GoBroad Hospital is dedicated to solving complex and critical illness problems. It closely integrates "research" and "clinical" functions, forming a specialized clinical trial team. Led by top researchers (PIs) and supported by a dedicated research team, they are committed to conducting clinical trials that meet international standards. Currently, Beijing GoBroad Hospital is conducting a series of clinical trial projects, with a focus on gastrointestinal and hematologic malignancies. If you're interested in participating, you can add the corresponding research doctor to assess whether you meet the enrollment criteria. Gastrointestinal Oncology Clinical Trial Recruitment Clinical Trial: A Phase III study comparing the safety and efficacy of Lutetium-177 ([177Lu]) oxytocin injection versus long-acting octreotide in adult patients with gastrointestinal pancreatic neuroendocrine tumors. Recruitment Criteria: Patients diagnosed with low or intermediate grade (G1 or G2) inoperable, locally advanced, or metastatic gastrointestinal pancreatic neuroendocrine tumors, who have previously undergone treatment with standard dose somatostatin analogs and showed progression.Clinical Trial: A Phase III study evaluating the efficacy and safety of ASK589 injection or placebo in combination with CAPOX (Oxaliplatin and Capecitabine) and PD-1 inhibitors as first-line treatment for CLDN18.2 positive, inoperable, locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma. Recruitment Criteria: Patients with histologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma, and who have been diagnosed with advanced, recurrent, or metastatic disease by imaging.Clinical Trial: A Phase III randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of M108 monoclonal antibody injection versus placebo in combination with CAPOX (Oxaliplatin and Capecitabine) for the treatment of locally advanced, inoperable, or metastatic CLDN18.2 positive, HER2 negative, PD-L1 CPS<5 gastric or gastroesophageal junction adenocarcinoma. Recruitment Criteria: Patients with advanced gastric or gastroesophageal junction adenocarcinoma who have not previously received systemic treatment.Clinical Trial: An open-label, multi-center Phase Ib/II study evaluating the safety and efficacy of LBL-024 in combination with etoposide and platinum-based chemotherapy as first-line treatment for advanced neuroendocrine carcinoma (NEC). Recruitment Criteria: Patients with histologically and/or cytologically confirmed, inoperable, locally advanced, or metastatic extrapulmonary NEC at the Phase II stage. If you are interested in participating in gastrointestinal oncology clinical trials, please contact us. Our research doctor will preliminarily assess whether you meet the enrollment criteria for this study. We will strictly maintain the confidentiality of your personal information and welcome your registration and participation. For gastrointestinal oncology research, please add the research doctor's WeChat for an initial review. Lymphoma and Myeloma Department Clinical Trial Recruitment 1.Clinical Trial: A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of JL1132 in the treatment of relapsed/refractory hematologic tumors. Patient Recruitment: Patients diagnosed with relapsed/refractory hematologic malignancies (multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome) who have failed prior standard treatment regimens, have no standard treatment options, or cannot tolerate existing treatments. 2.Clinical Trial: A Phase I clinical study to evaluate the safety, tolerability, and efficacy of the universal LUCAR-G39P cell therapy targeting CD19/CD20 dual antigens in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. Patient Recruitment: Patients with histologically confirmed diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or indolent lymphoma undergoing histological transformation to diffuse large B-cell lymphoma. 3.Clinical Trial: A multicenter clinical study on the use of GPRC5D-targeted chimeric antigen receptor (CAR) T-cell injection for the treatment of relapsed/refractory multiple myeloma. Patient Recruitment: Patients with measurable lesions in multiple myeloma who have failed prior treatments involving at least three different drug classes, including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. If you are interested in participating in the lymphoma and myeloma clinical trials, please contact us. Our research doctor will preliminarily assess whether you meet the enrollment criteria for this study. We will strictly maintain the confidentiality of your personal information and welcome your registration and participation. For lymphoma and myeloma research, please add the research doctor's WeChat for an initial review.
2024-12-5 -
Clinical Trial | Recruitment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Our hospital is conducting a randomized, double-blind, placebo-controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of M108 monoclonal antibody injection combined with CAPOX, compared to placebo, in patients with CLDN18.2-positive, HER2-negative, PD-L1 CPS <5 advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Study Drug The investigational drug is M108 monoclonal antibody injection. M108 monoclonal antibody injection is an anti-tumor therapy that targets specific molecules on the surface of cancer cells, inducing immune cells to attack and destroy the tumor cells, thereby inhibiting tumor progression and metastasis.Treatment Groups Study Group: M108 monoclonal antibody injection + capecitabine + oxaliplatin Control Group: Placebo injection + capecitabine + oxaliplatin Main Inclusion Criteria for Participation in this Study Age 18-75 years (inclusive of boundaries). Advanced gastric or gastroesophageal junction adenocarcinoma, with no prior systemic treatment (for those who have received neoadjuvant/adjuvant chemotherapy, please consult the contact person). Availability of a certain number of archival tumor pathology tissue samples or fresh biopsy tissue for testing. No significant organic diseases (if uncertain, please consult the contact person). Please Note: Whether you meet the inclusion criteria will be determined by the final comprehensive examination results and evaluation by the study doctor. Contact Us If you are interested in participating in this study, please contact us. The study doctor will initially assess whether you meet the study’s inclusion criteria. We will strictly maintain the confidentiality of your personal information. We welcome your application and participation. Add the study doctor on WeChat for preliminary screening. Expert Introduction
2024-11-15 -
Clinical Trial | Recruitment for B-Cell Non-Hodgkin Lymphoma Patients
Relapse after autologous CAR-T therapy in lymphoma patients remains a significant clinical challenge. Existing comprehensive clinical data suggest that dual-target CAR-T therapy can achieve a longer progression-free survival (PFS) compared to single-target CAR-T therapy, effectively delaying or reducing relapse. To date, clinical research on dual-target CAR-T therapy for relapsed/refractory hematological diseases has made significant progress. Dual-target CAR-T therapies targeting CD19/CD20, CD19/CD22, CD19/BCMA, or BCMA/CS1, after demonstrating strong anti-tumor activity in preclinical studies, have entered clinical trial stages. Multi-target CAR-T may become a trend in future cellular immunotherapy research. Beijing GoBroad Hospital is conducting a Phase I clinical study titled “Evaluation of the safety, tolerability, and efficacy of the universal LUCAR-G39P cell product targeting CD19/CD20 in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma,” which has been approved by the Ethics Committee. Recruitment for B-cell non-Hodgkin lymphoma patients is currently ongoing. 4o mini Inclusion Criteria If you meet the following conditions, you may contact us: Age ≥18-75 years (including boundary values); ECOG score 0-1 (independent in daily living); Histologically confirmed diagnoses of large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or indolent lymphoma with histological transformation to diffuse large B-cell lymphoma; CD19 and/or CD20 positive; Age-appropriate women with a negative pregnancy test. Please Note: The above are part of the primary criteria. The final inclusion criteria will be determined by the research physician and based on relevant test results. Contact Us Participants in this study may benefit from the treatment, but there are also potential risks. This study will provide the study medication and related exams, with some transportation reimbursement. If you would like to learn more about this study, please contact us. We welcome your enrollment and participation. Add the research physician’s WeChat for preliminary screening. Expert Introduction
2024-11-15 -
Clinical Trial | Recruitment for Advanced Neuroendocrine Carcinoma (NEC) Patients
Our hospital is conducting a clinical trial initiated by Nanjing Weilizhibo Biotechnology Co., Ltd. titled "An Open-Label, Multicenter Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of LBL-024 in Combination with Etoposide and Platinum-based Chemotherapy as First-Line Treatment in Advanced Neuroendocrine Carcinoma (NEC) Patients" (Protocol No. LBL-024-CN002). Investigational Drug The investigational drug is LBL-024 for injection, a bispecific anti-PD-L1/4-1BB antibody independently developed by Nanjing Weilizhibo Biotechnology Co., Ltd. The objective of the study is to evaluate the safety, tolerability, and efficacy of LBL-024 in combination with etoposide and platinum-based chemotherapy as first-line treatment for patients with advanced neuroendocrine carcinoma.Approximately 20 top-tier hospitals nationwide will participate in this study, with around 68 patients (the specific sample size will depend on actual conditions) taking part in the research. The study has been approved by the National Medical Products Administration (NMPA) and the ethics committee of our hospital. Main Inclusion Criteria for Participation in This Study Agree to follow the study treatment plan and visit schedule, voluntarily enroll, and provide written informed consent. Age must be between 18 and 75 years old (inclusive) at the time of signing the informed consent form. In Phase II of the study, patients with histologically and/or cytologically confirmed, unresectable locally advanced or metastatic extra-pulmonary neuroendocrine carcinoma (NEC) will be included. Patients who have not received prior systemic treatment for advanced NEC. If the patient has received neoadjuvant or adjuvant treatment and relapsed or metastasized more than 6 months after the last dose, they are eligible for inclusion (except those who have previously received anti-PD(L)-1 antibody therapy). Agree to provide archived tissue or fresh biopsy tumor samples for biomarker testing. Please Note: Eligibility for enrollment will be determined by the comprehensive examination results and the research physician's evaluation. Contact Us If you are interested in participating in this study, please contact us, and the research physician will assess your eligibility based on preliminary evaluation. We will strictly keep your personal information confidential. We welcome your registration and participation. Add the research physician’s WeChat for preliminary screening. Expert Introduction
2024-10-11
- 1
